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Adrenal Beta-Arrestin 1 Inhibition In Vivo Attenuates
Post-Myocardial Infarction Progression to Heart
Failure and Adverse Remodeling Via Reduction
of Circulating Aldosterone Levels
Anastasios Lymperopoulos, PHD,*† Giuseppe Rengo, MD,†§ Carmela Zincarelli, MD,†
Jihee Kim, PHD,‡ Walter J. Koch, PHD†
Fort Lauderdale, Florida; Philadelphia, Pennsylvania; Durham, North Carolina; and Telese Terme, Italy
Objectives We investigated whether adrenal beta-arrestin 1 (arr1)-mediated aldosterone production plays any role in post-
myocardial infarction (MI) heart failure (HF) progression.
Background Heart failure represents 1 of the most significant health problems worldwide, and new and innovative treat-
ments are needed. Aldosterone contributes significantly to HF progression after MI by accelerating adverse car-
diac remodeling and ventricular dysfunction. It is produced by the adrenal cortex after angiotensin II activation of
angiotensin II type 1 receptors (AT1Rs), G protein-coupled receptors that also signal independently of G proteins.
The G protein-independent signaling is mediated by arr1 and arr2. We recently reported that adrenal arr1
promotes AT1R-dependent aldosterone production leading to elevated circulating aldosterone levels in vivo.
Methods Adrenal-targeted, adenoviral-mediated gene delivery in vivo in 2-week post-MI rats, a time point around which
circulating aldosterone significantly increases to accelerate HF progression, was performed to either increase the
expression of adrenal arr1 or inhibit its function via expression of a arr1 C-terminal-derived peptide fragment.
Results We found that adrenal arr1 overexpression promotes aldosterone elevation after MI, resulting in accelerated
cardiac adverse remodeling and deterioration of ventricular function. Importantly, these detrimental effects of
aldosterone are prevented when adrenal arr1 is inhibited in vivo, which markedly decreases circulating aldoste-
rone after MI. Finally, the prototypic AT1R antagonist losartan seems unable to lower this adrenal arr1-driven
aldosterone elevation.
Conclusions Adrenal arr1 inhibition, either directly or with AT1R “biased” antagonists that prevent receptor-arr1 coupling,
might be of therapeutic value for curbing HF-exacerbating hyperaldosteronism. (J Am Coll Cardiol 2011;57:
356–65) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.635t
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reath due to chronic heart failure (HF) continues to rise,
espite recent advances in prevention and management of
eart disease, and new treatments are needed (1,2). Aldoste-
one is 1 of a number of hormones with detrimental effects to
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010, accepted August 17, 2010.he myocardium, where circulating levels are elevated in
hronic HF (3). It can contribute significantly to HF progres-
ion after myocardial infarction (MI) and to the morbidity and
ortality of the disease (3–5). Its main actions on the post-MI
eart include but are not limited to cardiac hypertrophy,
brosis, and increased inflammation and oxidative stress, all of
hich result in adverse cardiac remodeling and progressive
oss of cardiac function and performance (5,6). Accordingly,
lasma aldosterone levels are a marker of HF severity (7,8),
nd aldosterone antagonists—such as spironolactone and
plerenone—have well-documented beneficial effects in
F, constituting a significant segment of the chronic HF
harmacotherapeutic regimen (9,10).
Aldosterone is a mineralocorticoid produced and secreted by
he cells of the zona glomerulosa of the adrenal cortex in
esponse to either elevated serum potassium levels or to
ngiotensin II (AngII) acting through its type 1 receptors
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January 18, 2011:356–65 Beta-Arrestin 1 and Aldosterone in HFAT1Rs), endogenously expressed in the adrenocortical zona
lomerulosa (AZG) cells (11). The AT1Rs belong to the
uperfamily of G protein coupled receptors (GPCRs) and,
pon agonist activation, couple to the Gq/11 family of G
roteins (12). Over the past few years, a number of GPCRs,
ncluding the AT1Rs, have been shown to also signal through
protein-independent pathways. The protein scaffolding
ctions of -arrestin-1 and -2 (arr1 and arr2, also known as
rrestins-2 and -3, respectively), universal receptor adapter/
caffolding proteins originally discovered as terminators of
PCR signaling, play a central role in mediating this G
rotein-independent signal transduction (13,14).
We recently reported that adrenal arr1 promotes AngII-
ependent aldosterone production in vitro in human AZG
ells, independently of G-proteins (15). Additionally,
drenal-specific arr1 overexpression in vivo resulted in a
arked elevation of circulating aldosterone levels in other-
ise normal animals (15). In the present study, we sought to
nvestigate whether adrenal arr1 plays any role in regula-
ion of circulating aldosterone levels in post-MI HF pro-
ression as well. For this purpose, we used our previously
eveloped methodology for adrenal-targeted gene transfer
n vivo (16,17), in 2-week post-MI rats, of either wild-type
arr1 to induce adrenal arr1 overexpression or of a arr1
rotein fragment comprising the arr1 C-terminus, which
nhibits arr1 signaling activity. The 2-week post-MI time
oint was chosen, because at approximately this time point,
irculating aldosterone levels increase dramatically to accel-
rate post-MI HF progression in rats (18,19).
ethods
n vivo adrenal gene delivery in post-MI rats. All animal
rocedures and experiments were performed in accordance
ith the guidelines of the Institutional Animal Care and
se Committees of Thomas Jefferson and Nova Southeast-
rn Universities. Myocardial infarction was performed with
cryo-infarct method we have previously described (16).
drenal-specific in vivo gene delivery was done essentially
s described (17), via direct delivery of adenovirus in the
drenal gland. Drug treatments were performed with 50
g/kg/day of losartan potassium (in drinking water) and
00 or 5 mg/kg/day eplerenone (both drugs from Sigma-
ldrich, St. Louis, Missouri).
onstruction and purification of adenoviruses. Recom-
inant adenoviruses that encode full-length wild-type arr1
Adarr1) or a rat arr1 C-terminal fragment (aa. 369-418,
darr1ct) (Online Fig. 1A) were constructed as described
reviously (15,16). Briefly, transgenes were cloned into
huttle vector pAdTrack-cytomegalovirus, which harbors a
ytomegalovirus-driven green fluorescent protein (GFP), to
orm the viral constructs with standard cloning protocols. As
ontrol adenovirus, empty vector that expressed only GFP
AdGFP) was used. The resultant adenoviruses were purified,
s described previously, with 2 sequential rounds of cesium
hloride density gradient ultracentrifugation (15,16). Clasma aldosterone measure-
ents. Rat plasma aldosterone
evels were determined by EIA
Aldosterone EIA kit, ALPCO
iagnostics, Salem, New Hamp-
hire), as described (15,20).
chocardiographic and hemo-
ynamic measurements. Two-
imensional guided M-mode and
oppler echocardiography with a
4-MHz transducer (Vevo 770
chograph, VisualSonic, Inc., To-
onto, Canada) and closed chest
ardiac catheterization were per-
ormed in rats, as described previ-
usly (16,21). Three independent
chocardiographic measurements
ere taken in both modes.
estern blotting. Western blots
o assess protein levels of steroido-
enic acute regulatory (StAR) pro-
ein (sc-25806), cardiac levels of
lasminogen activator inhibitor
PAI)-1 (sc-8979), transforming
rowth factor (TGF)- (sc-1460),
arr1 transgenes (A1CT antibody,
generous gift from Dr. R.J. Lef-
owitz, Duke University Medical
enter, Durham, North Carolina),
nd glyceraldehyde-3-phosphate
ehydrogenase (MAB374, Chemi-
on, Temecula, California) were
one with protein extracts from rat
drenal glands or hearts, as de-
cribed previously (15,16). Visual-
zation of Western blot signals was
erformed with Alexa Fluor 680–
Molecular Probes, Eugene, Ore-
on) or IRDye 800CW–coupled
Rockland, Inc., Gilbertsville,
ennsylvania) secondary antibod-
es on a LI-COR infrared imager
Odyssey, Li-COR Biosciences,
incoln, Nebraska).
eal-time polymerase chain reaction (PCR). Total heart
ibonucleic acid (RNA) isolation and reverse transcription
RT) and real-time PCR were performed as previously de-
cribed (16,21). The following primer pairs were used: 5=-
TCCACGAGGTGACAAAGGT-3 = and 5 =-
ATCTTTTCCAGGAGGTCCA-3= for Col31;
=-CACCCCTTCTGCGTTGTATT-3= and 5=-
TGACCCTAACCAAGGATGC-3= for Col11; 5=-
GCCTGCACCTTTGTGATATCG-3= and 5=-
ATGGCAGGACAATCGAACC-3= for B-type
atriuretic peptide (NPR-B); 5=-CATCCTGGA-
Abbreviations
and Acronyms
Adarr1  adenoviruses
that encode full-length wild-
type beta-arrestin 1
Adarr1ct  adenoviruses
that encode rat beta-
arrestin 1 C-terminal
fragment
AdGFP  adenovirus green
fluorescent protein
AngII  angiotensin II
AT1R  angiotensin II
receptor type I
AZG  adrenocortical zona
glomerulosa
arr1  beta-arrestin 1
arr1ct  beta-arrestin 1
C-terminal fragment
EF  ejection fraction
GPCR  G-protein coupled
receptor
GRK2  G-protein coupled
receptor kinase-2
HF  heart failure
LVEDD  left ventricular
end diastolic diameter
MI  myocardial infarction
MR  mineralocorticoid
receptor
PAI  plasminogen
activator inhibitor
PCR  polymerase chain
reaction
RAAS  renin-angiotensin-
aldosterone system
RNA  ribonucleic acid
RT  reverse transcription
StAR  steroidogenic
acute regulatory (protein)
TGF  transforming growth
factorAACCTGC-3= and 5=-TAGGTCCGAACCTTGCC-3=
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Beta-Arrestin 1 and Aldosterone in HF January 18, 2011:356–65or atrial natriuretic peptide (ANP) (NPR-A); and finally,
=-TCAAGAACGAAAGTCGGAGG-3= and 5=-
GACATCTAAGGGCATCAC-3= for 18S ribosomal
NA. Real time RT-PCR was performed with SYBR Green
upermix (Bio-Rad, Hercules, California). Normalization was
one with 18S ribosomal RNA levels. No bands were seen in
he absence of RT.
asson-trichrome staining. Masson-trichrome staining
as performed as described (22).
tatistical analyses. Data are generally expressed as mean
EM. Unpaired 2-tailed Student t test and 1- or 2-way
nalysis of variance with Bonferroni test were generally per-
ormed for statistical comparisons, unless otherwise indicated.
or most 3-group statistical comparisons, Dunnett’s test with
AS version 8.2 software (SAS, Cary, North Carolina) was
sed as well. For all tests, a p value of 0.05 was generally
onsidered to be significant.
esults
drenal arr1 and post-MI aldosterone levels. In the
resent study, we set out to investigate the potential role played
y adrenal arr1 in modulation of in vivo post-MI HF
ldosterone levels. To this end, we overexpressed—specifically
n the adrenal glands of 2-week post-MI rats—wild-type arr1
r a arr1 C-terminal fragment (arr1ct), which is unable to
ind receptor substrates, thus acting as an inhibitor of arr1
caffolding/signaling activity (Online Fig. 1A). To confirm the
nhibitory effects of arr1ct on arr1 activity in vitro, we
erformed an extensive molecular characterization of its effects
n AngII-induced signaling to aldosterone production in the
uman AZG cell line H295R (Online Fig. 1B). The arr1ct
as indeed found to abrogate arr1- and G protein-mediated
ignaling from AT1R to extracellular signal-regulated kinase
ctivation and StAR protein up-regulation; both signaling
vents are absolutely necessary for AngII-driven aldosterone
roduction and secretion from these adrenocortical cells (15)
Online Fig. 1B). Thus, after confirming that arr1ct acts as an
nhibitor of adrenal arr1-mediated aldosterone production in
Figure 1 Regulation of Plasma Aldosterone Levels by Adrenal 
Plasma aldosterone levels in AdGFP-, Adarr1-, or Adarr1ct-treated 2-week post-m
AdGFP, **p  0.05 versus Adarr1, n  6 rats/group. AdGFP  adenovirus green
arrestin 1; Adarr1ct  adenoviruses that encode rat beta-arrestin 1 C-terminal fraitro, we overexpressed either the full-length arr1 (to increase
drenal arr1 levels/activity) or the arr1ct (to inhibit adrenal
arr1 activity in vivo) specifically in the adrenals of the
ost-MI rats. Experimental animals were randomized to 3
ifferent groups: 1 group receiving adrenal gene transfer of
dGFP (control group), 1 receiving full-length wild-type
arr1 (Adarr1), and 1 receiving the arr1ct (Adarr1ct). One
ay before adrenal gene transfer, all groups were analyzed by
chocardiography to confirm presence of similar levels of left
entricular dysfunction and HF before gene delivery. All
roups were then studied over the course of the following 7
ays (i.e., up to 3 weeks after MI).
In vivo expression of the respective transgenes in the adrenal
lands of the animals at 7 days after gene delivery was
onfirmed by Western blotting (Online Fig. 2). Of note, the
drenal-targeted gene transfer methodology employed results
n no ectopic transgene expression (17) (data not shown). As
xpected, plasma circulating aldosterone levels at 7 days after
ene delivery were found markedly elevated in control
dGFP-treated post-MI rats (470 20 pg/ml, approximately
-fold of the aldosterone levels of normal AdGFP-treated rats)
15), compared with normal (i.e., sham-operated) AdGFP-
reated rats, indicating marked MI-induced aldosterone eleva-
ion. Importantly, adrenalarr1 overexpression resulted in an even
ore pronounced aldosterone elevation after MI, on top of that
ormally present due to the occurrence of MI (845 150 pg/ml
n Adarr1-treated versus 470  20 pg/ml in control AdGFP-
reated post-MI rats, n 6, p 0.05) (Fig. 1). In contrast, levels
n Adarr1ct-treated rats (350 30 pg/ml, n 6, p 0.05 vs.
dGFP) were significantly lower than in control AdGFP-
reated post-MI rats (Fig. 1). Aldosterone levels in post-MI
dGFP rats were similar to saline-treated post-MI rats (data
ot shown), indicating no nonspecific effects of the adenovi-
uses used on plasma aldosterone values.
Consistent with the aforementioned findings, arr1 over-
xpression led to significant up-regulation of adrenal StAR
rotein, the most critical enzyme in adrenocortical biosyn-
hesis of aldosterone (as well as of the other adrenal steroids)
dial infarction rats at 7 days after in vivo gene delivery. *p  0.05 versus
scent protein; Adarr1  adenoviruses that encode full-length wild-type beta-
t.arr1
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January 18, 2011:356–65 Beta-Arrestin 1 and Aldosterone in HF15), compared with control AdGFP-treated post-MI rats,
ndicating enhanced aldosterone synthesis in vivo, whereas
verexpression of arr1ct reduced adrenal StAR levels
elow the levels of the control rats (Online Fig. 2). Taken
ogether, these results indicate that adrenal arr1 promotes
ost-MI-associated hyperaldosteronism, and inhibition of
ts activity reduces aldosterone production and plasma
irculating aldosterone levels after MI in vivo.
Figure 2 Effect of Adrenal arr1-Mediated Hyperaldosteronism
(A) Ejection fraction (EF%) of Adarr1- and control AdGFP-treated post-myocardial i
AdGFP after gene delivery or Adarr1 before gene delivery; **p  0.05 versus AdG
(LVEDD) of these rats. *p  0.05 versus AdGFP after gene delivery or Adarr1 be
post-MI rats administered either with saline (vehicle) or with eplerenone (Adarr1-E
rats (treated with vehicle) are also shown at 1 week after gene delivery (3 weeks a
significant difference between AdGFP and Adarr1-Eplerenone was observed at p 
stimulated dP/dtmax (E) and dP/dtmin (F) responses of Adarr1- and control A
*p  0.05 versus AdGFP, n  7 rats/group. Abbreviations as in Figure 1.n vivo cardiac function and dimensions at 7 days after
ene delivery. Next, we examined the impact of this
drenal arr1-mediated hyperaldosteronism on the post-MI
yocardium. Indeed, we found that ejection fraction (EF)
as markedly reduced in Adarr1-treated post-MI rats at 7
ays after gene delivery, compared with control AdGFP-
reated post-MI rats (41.4  1.2% vs. 48.7  1.1%,
espectively, n  7, p  0.05) (Fig. 2A). The EF in both
ardiac Function, Dimensions, and Contractility
on (MI) rats before and after gene delivery (see also Table 1). *p  0.05 versus
-gene delivery, n  7 rats/group. (B) Left ventricular end diastolic diameter
ne delivery, n  7 rats/group. (C) The EF% and (D) LVEDD of Adarr1-treated
one) for 7 days, at 1 week after gene delivery (3 weeks after MI). AdGFP post-MI
I) for comparisons. *p  0.05 versus either AdGFP or Adarr1-Eplerenone; no
, n  5 rats/group. (E, F) Basal and maximal dose of isoproterenol (Max. Iso)-
reated post-MI rats at 7 days after adrenal gene delivery (see also Table 1).on C
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Beta-Arrestin 1 and Aldosterone in HF January 18, 2011:356–65roups was similar before gene delivery, and EF of AdGFP-
reated rats at 7 days after gene delivery was slightly but
ignificantly reduced compared with pre-gene delivery, as
xpected, given that cardiac function deteriorates over time
fter MI, although at 3 weeks after MI (when post-gene
elivery measurements were taken) there is limited dysfunc-
ion with this model (Fig. 2A). Indeed, previous studies by
s have shown that this model in the rat does not lead to
ignificant cardiac dysfunction before approximately 10
eeks after MI (21). Furthermore, left ventricular end
iastolic diameter (LVEDD), a marker of cardiac dimen-
ions, was significantly increased in Adarr1-treated rats at
weeks after MI compared with control AdGFP post-MI
ats, in which heart enlargement was less pronounced at 3
eeks after MI (Fig. 2B). This indicates that adrenal arr1
verexpression significantly accelerates the progression of
ardiac hypertrophy by promoting aldosterone elevation
fter MI. Of note, EF and LVEDD of saline-treated,
-week, post-MI rats were similar to those of control
dGFP-treated post-MI rats at 7 days after gene delivery,
ndicating no nonspecific effects of the adenoviral gene
elivery on cardiac function (data not shown).
Importantly, these adrenal arr1-induced cardiac alter-
tions are aldosterone-mediated (i.e., due to the elevated
ldosterone levels caused by adrenal arr1 overexpression in
ivo), because EF reduction and LVEDD increase are
revented (i.e., are similar to control AdGFP-treated rats)
n Vivo Cardiac Functional Parameters After Adrenal Gene DeliveryTable 1 In Vivo Cardiac Functional Parameters After Adrenal G
Sham-Operated (n 
Echocardiographic parameters after gene delivery
LVIDs (mm) 3.76 0.08
LVEDD (mm) 6.36 0.15
FS (%) 37.09 1.39
EF (%) 65.01 1.77
PWTd (mm) 1.25 0.08
Basal LV hemodynamic measurements
HR (beats/min) 354.2 13.9
LV dP/dtmax (mm Hg/s) 9,997 446
LV dP/dtmin (mm Hg/s) 8,598 248
LVESP 120.6 1.1
LVEDP 1.7 0.6
Hemodynamic measurements after maximal
isoproterenol (333 ng/kg BW)
HR (beats/min) 434.2 13.2
LV dP/dtmax 15,128 391
LV dP/dtmin 9,981 115
LVESP 127.9 1.8
LVEDP 1.9 0.9
Phenotypic data
HW/BW ratio (mg/g) 2.03 0.16
drenal gene delivery of adenovirus green fluorescent protein (AdGFP), adenoviruses that encode
ragment (Adarr1ct) was performed at 2 weeks after myocardial infarction, and the paramet
ge-matched, sham-operated animals are shown for comparisons. Analysis of variance with Bon
ham-operated; †p  0.05 versus AdGFP; ‡p  0.05 versus Adarr1.
BW  body weight; EF  ejection fraction; FS  fractional shortening; HR  heart rate; LV
erivative of left ventricular pressure fall; LVEDD  left ventricular end-diastolic diameter; LVEDP  l
eft ventricular inner diameter during systole; PWTd  posterior wall thickness in diastole.y treatment of post-MI Adarr1 rats with the aldosterone
ntagonist eplerenone (Figs. 2C and 2D), although this
rug—as expected—has no effect on the plasma aldosterone
ncrease caused by the Adarr1 treatment of the adrenals of
hese post-MI animals (Online Fig. 3). Of note, eplerenone
revented the effects of adrenal arr1 overexpression at 2
ompletely different doses (a high dose, 100 mg/kg/day
Figs. 2C and 2D], and a low dose, 5 mg/kg/day [data not
hown]). Thus, the cardiac effects observed upon adrenal arr1
verexpression are indeed mediated by circulating aldosterone.
Finally, hemodynamic analysis revealed that Adarr1-
reated post-MI rats exhibited significantly reduced basal
nd maximal dose of isoproterenol-induced cardiac contrac-
ion and relaxation indexes, compared with control
dGFP-treated rats (Figs. 2E and 2F). At this early
ost-MI time point, when cardiac dysfunction has not yet
anifested as HF, echocardiographic and hemodynamic
arameters of Adarr1ct-treated post-MI rats did not
isplay statistically significant differences from those of
ontrol AdGFP-treated post-MI rats, as one might expect,
lthough there was some trend toward functional improve-
ent in the Adarr1ct group (see Table 1 for complete in
ivo cardiac functional parameters in all 3 post-MI groups at
week after gene delivery). These results show that the
drenal arr1-mediated hyperaldosteronism indeed results
n significantly accelerated deterioration of function of the
ost-MI rat heart.
elivery
AdGFP (n  7) Adarr1 (n  7) Adarr1ct (n  7)
6.6 0.04* 7.2 0.04*† 6.0 0.04*‡
8.7 0.25* 9.5 0.15*† 7.9 0.5*‡
25.6 0.7* 21.3 0.7*† 28.6 2.7*‡
48.7 1.1* 41.4 1.2*† 52.3 2.9*‡
1.6 0.04* 2.0 0.2*† 1.4 0.24*‡
352.8 16.2 363.6 7.8 356.8 14.2
7,549 512* 5,820 88.5*† 8,149 512*‡
6,157 392* 5190 110*† 6,657 392*‡
115.0 4.7 104.2 4.4*† 118.0 3.7‡
2.8 0.4 8.2 1.0*† 2.3 0.4‡
437 15.0 452 13.0 447 16.0
11,200 668* 9,742 291*† 11,900 668*‡
7,509 496* 6,646 171*† 8,209 496*‡
122.0 4.9 111.2 2.3*† 124.0 4.6‡
3.1 0.4 8.8 0.9*† 2.8 0.4‡
2.7 0.16* 3.3 0.21*† 2.5 0.11*‡
th wild-type beta-arrestin 1 (Adarr1), or adenoviruses that encode rat beta-arrestin 1 C-terminal
he table were measured 7 days after gene delivery (direct adrenal gland injection). Values of
test was performed among all groups. Data are presented as mean  SEM. *p  0.05 versus
max  maximal first derivative of left ventricular pressure rise; LV dP/dtmin  minimal firstene D
6)
full-leng
ers in t
ferroni
dP/dt
eft ventricular end diastolic pressure; LVESP  left ventricular end systolic pressure; LVIDs 
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January 18, 2011:356–65 Beta-Arrestin 1 and Aldosterone in HFardiac remodeling and functional biomarkers at 7 days
fter gene delivery. We also performed molecular and
tructural evaluation of the post-MI rat hearts at 7 days after
ene delivery. Real time PCR in total messenger RNA
solated from these hearts showed—consistent with the in
ivo functional data—a marked up-regulation of collagen
ypes 11 and 31, markers of cardiac fibrosis, and of ANP
nd B-type natriuretic peptide, markers of cardiac hyper-
rophy, in the post-MI hearts of Adarr1-treated rats,
ompared with control AdGFP-treated animals (Figs. 3A
o 3D). Conversely, up-regulation of all these markers was
revented in Adarr1ct-treated rats (Figs. 3A to 3D), even
hough this group did not show significant improvement in
ardiac function, which is not surprising given the early
ost-MI time point at which these measurements were
aken. Thus, lowering of circulating aldosterone levels by
drenal arr1 inhibition in vivo causes a marked reduction
n the expression of adverse remodeling-related genes,
hich might help halt the post-MI cardiac decline at later
ime points. Additionally, heart-weight/body-weight ratio
easurements also confirmed the accelerated cardiac hyper-
rophy (i.e., enhanced at 1 week after adrenal gene delivery,
ompared with control AdGFP-treated) displayed by
darr1-treated post-MI rats (Table 1, see also preceding
Figure 3 Effect of Aldosterone Levels on Cardiac Remodeling M
Heart messenger ribonucleic acid (mRNA) levels of (A) collagen I (Col1a1); (B) co
(BNP) in all experimental groups at 7 days after gene delivery (3 weeks after myoc
are presented as mean  SEM and plotted as fold of AdGFP values. *p  0.05 v
ations as in Figures 1 and 2.ext, Fig. 2B). mardiac fibrosis at 7 days after gene delivery. Masson-
richrome staining for cardiac fibrosis at 3 weeks after MI
7 days after gene delivery) showed markedly increased
brosis in Adarr1-adrenal-treated rat hearts compared
ith control AdGFP-treated rat hearts, whereas fibrosis
as almost completely absent in Adarr1ct-adrenal-
reated rat hearts (Figs. 4A and 4B). As expected, no fibrosis
as detectable in sham-operated rat hearts (Fig. 4A). In
ddition, eplerenone treatment markedly reduced fibrosis in
darr1-adrenal-treated rat hearts (Online Fig. 4), thus
roviding another indication that the cardiac effects of arr1
re aldosterone-dependent.
ardiac mediators of aldosterone at 7 days after gene
elivery. Immunoblotting in cardiac protein extracts re-
ealed a marked up-regulation of cardiac PAI-1 and TGF-
—2 of the most important molecular mediators of the
ardiac fibrotic and adverse remodeling actions of aldosterone
5)—in the post-MI hearts of Adarr1-treated rats compared
ith control AdGFP-treated rats (Figs. 4C and 4D). In
ontrast, in the hearts of Adarr1ct-treated rats, not only
as up-regulation of PAI-1 and TGF- prevented but the
evels of these proteins were actually lowered below the
evels of control AdGFP-treated rats (Figs. 4C and 4D).
aken together, these results indicate that adrenal arr1-
rs
III (Col3a1); (C) atrial natriuretic peptide (ANP); and (D) brain natriuretic peptide
infarction). All values were standardized to amplified 18S ribosomal RNA. Data
AdGFP or Adarr1ct; **p  0.05 versus AdGFP, n  5 rat hearts/group. Abbrevi-arke
llagen
ardial
ersusediated hyperaldosteronism accelerates cardiac adverse
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ffects can be reciprocally mitigated by adrenal arr1 inhi-
ition, which significantly reduces circulating aldosterone
evels.
ngiotensin antagonism and arr1-mediated aldosterone
evels after MI. Finally, we examined whether adrenal
arr1 can affect the efficacy of AT1R antagonism at curbing
ngII-induced aldosterone production. For this purpose,
e treated post-MI rats with the prototypic AT1R antag-
nist losartan (23,24) for the entire 7-day post-gene delivery
eriod at a dose of 50 mg/kg/day. As expected, in control
dGFP-treated post-MI rats, losartan produced a small but
ignificant plasma aldosterone reduction (from 470  20
g/ml in saline-treated to 402  10 pg/ml in losartan-
reated rats, p  0.05, n  6) (Fig. 5). In Adarr1-treated
ost-MI rats however, losartan is virtually unable to lower
ldosterone levels (845  150 pg/ml in saline-treated vs.
80  88 pg/ml in losartan-treated rats, not significant at p
0.05, n 6) (Fig. 5). In the Adarr1ct-treated group, no
ignificant aldosterone reduction by losartan was observed,
robably because plasma aldosterone levels were already
educed below the levels of AdGFP-treated rats by
darr1ct alone. Consistent with this, losartan seems also
ncapable of reducing the cardiac fibrosis induced by adrenal
Figure 4 Impact of Aldosterone Levels on Cardiac Fibrosis and
(A) Trichrome-Masson’s staining in myocardial cross sections from AdGFP-, Adar
denotes collagen fibers, red denotes muscle fibers, and black represents cell nuc
staining in sham rat hearts, in which no blue staining was detectable. (B) Quantifi
versus AdGFP; **p  0.05 versus Adarr1, n  5 to 6 rat hearts/group. (C) Wes
factor- (TGF-1) in AdGFP-, Adarr1-, or Adarr1ct-treated post-MI rats at 7 days a
loading control. (D) Densitometric analysis of 5 heart samples tested/group. *p 
tions as in Figures 1, 2, and 3.arr1-mediated hyperaldosteronism (Online Fig. 4). How-ver, levels in both the saline- and losartan-treated
darr1ct rats were significantly lower than in vehicle-
dministered control AdGFP post-MI rats (Fig. 5). These
esults strongly suggest that the post-MI aldosterone-
owering effects of losartan are antagonized by adrenal
arr1; therefore adrenal arr1 inhibition can potentiate the
ypoaldosteronic actions of this drug in post-MI HF.
Figure 5 Adrenal arr1-Dependent Aldosterone Levels and
Losartan
Plasma aldosterone levels 7 days after adrenal gene delivery of post-myocar-
dial infarction rats after concomitant vehicle (Los) or losartan (Los) treat-
ment. *p  0.05 versus AdGFP/Los or Adarr1/Los, n  5 rats/group/
treatment. Abbreviations as in Figures 1, 2, and 3.
rse Remodeling Mediators
Adarr1ct-treated post-MI rats at 7 days after adrenal gene delivery. Blue
presentative images are shown from 5 to 6 rat hearts stained/group, along with
of the % fibrotic area visualized upon Trichrome-Masson’s staining. *p  0.05
lotting for cardiac plasminogen activator inhibitor (PAI)-1 and transforming growth
ene delivery, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
versus AdGFP; **p  0.05 versus Adarr1, n  5 rat hearts/group. Abbrevia-Adve
r1-, or
lei. Re
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ost-MI rats were similar (data not shown).
iscussion
e recently reported that adrenal arr1 promotes AngII-
ependent aldosterone production in vitro in human AZG
ells, independently of G-proteins (15). Additionally,
drenal-specific arr1 overexpression in vivo resulted in
arked elevation of circulating aldosterone levels in other-
ise normal animals (15). In the present study, we sought to
nvestigate whether adrenal arr1 plays any role in regula-
ion of circulating aldosterone levels in post-MI HF pro-
ression. We found that adrenal arr1 is indeed a crucial
egulator of circulating aldosterone levels in vivo during
ost-MI HF progression, in that increased adrenal arr1
evels/activity promote aldosterone elevation after MI, re-
ulting in accelerated cardiac adverse remodeling and dete-
ioration of function, whereas blockade of its activity in vivo
owers post-MI aldosterone levels, attenuating or even
reventing these detrimental effects of aldosterone on the
ailing heart.
These findings strongly suggest that blockade of adrenal
arr1 action on AT1R might serve as a novel therapeutic
trategy for lowering aldosterone levels after MI and in HF.
his is particularly important, because aldosterone has been
hown to exert some of its actions (its so-called “non-
enomic” actions) independently of the mineralocorticoid
eceptor (MR), its molecular target that normally mediates
ts cellular actions (4,5). These MR-independent actions are
naffected by the currently available MR antagonists, such
s eplerenone and spironolactone, used in the treatment of
F (9,10). Therefore, curbing aldosterone production at its
ajor source (i.e., the adrenal cortex) by inhibiting arr1
ctions could presumably be more effective therapeutically
han inhibiting the actions of aldosterone at its receptor
evel.
In addition, because adrenal arr1 seems necessary for
p-regulation of StAR, the enzyme that regulates synthesis
f all adrenal steroids, its inhibition presumably leads to
uppression of the production of the other adrenocortical
teroids as well (i.e., of glucocorticoids and corticosterone)
15). Of note, glucocorticoids have been reported to actually
ccupy the cardiac MRs under normal conditions instead of
ldosterone (25). Therefore, adrenal arr1 inhibition, by
uppressing production of glucocorticoids and mineralocor-
icoids alike, has the unique potential of keeping cardiac
Rs completely at bay. For this very same reason, adrenal
arr1 emerges as a much superior target for post-MI cardiac
emodeling and HF treatment than MR inhibition (e.g.,
ith eplerenone) or aldosterone synthase inhibition, given
hat the latter strategies cannot counter all the adverse
ffects of all adrenal steroids after MI, as suppression of all
drenal steroid production via adrenal arr1 inhibition is
rojected to do. aAnother important ramification of the present study is
hat pathological situations that cause elevation of adrenal
arr1 activity toward receptors can lead to abnormally high
ngII-induced aldosterone production and hyperaldoste-
onism. Indeed, we recently reported that in chronic HF,
drenal GRK2—a protein kinase that induces receptor-arr
oupling—is dramatically up-regulated, resulting in chron-
cally enhanced catecholamine production by the adrenal
edulla (16). Thus, it is entirely plausible that, driven by the
nhanced GRK2 activity, adrenal arr1 activity toward
eceptors—including the AT1Rs—is also increased in
hronic HF or during progression from MI to HF, which
ould mediate (at least in part) the chronically elevated
irculating levels of aldosterone that precipitate this disease.
mportantly, we have previously shown that GRK2 can
esensitize AngII receptors in the heart in vivo (26) and that
verexpression of GRK2 in rat adrenal glands also causes
levation of plasma aldosterone (15). Both of these findings
rgue in favor of the aforementioned scenario.
Furthermore, it is now well-established that, in addi-
ion to the circulatory renin-angiotensin-aldosterone sys-
em (RAAS), there are also several other local RAASs in
eripheral tissues, including the heart (intracardiac
AAS) and the kidneys (intrarenal RAAS), and these
ystems also hyperfunction in HF contributing to the
F-associated hyperaldosteronism (27,28). Therefore, it
ould be worth investigating whether arr1 is involved in
ldosterone production by these local RAASs and
hether it contributes to their increased aldosterone
utput during HF as well. In fact, specifically for the
ntracardiac RAAS, this possibility is very likely, given
he elevated cardiac GRK2 levels in HF (29).
One of the major physiological effects of aldosterone is an
ncrease in blood pressure via salt and water retention (4,5).
hus, alterations in mean arterial pressure by the elevated
ldosterone levels caused by adrenal arr1 overactivity
ight very well have contributed to the observed cardiac
henotype of adrenal arr1-overexpressing post-MI rats. It
hould be noted here, however, that arr1 knockout mice do
ot show any changes in blood pressure compared with
ild-type age-matched control mice (30). Additionally, the
irect effects of aldosterone on cardiac tissue are bound to
ave played the most important role in the observed cardiac
henotype of the post-MI animals, given the relatively small
ime period (only 7 days) between genetic manipulation of
drenal arr1 levels that raises aldosterone levels (i.e., gene
elivery) and the day of cardiac measurements/examination,
hich is rather insufficient for blood pressure to dramatically
ffect cardiac function and remodeling. Besides, whether
hanges in blood pressure play any role in the cardiac effects
f aldosterone is still an open question in its own right,
ecause there are several reports in the published literature
howing aldosterone to affect cardiac function and fibrosis in
ost-MI rats independently of changes in mean blood
ressure (31,32). Indeed, no differences in systemic mean
rterial pressure among the 3 post-MI treatment groups of
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Beta-Arrestin 1 and Aldosterone in HF January 18, 2011:356–65he present study (i.e., AdGFP, Adarr1, Adarr1ct) were
bserved at 1 week after gene delivery (data not shown),
urther supporting the notion that blood pressure did not
lay any major role in the observed cardiac effects of
arr1-dependent aldosterone at this early post-MI time
oint (3 weeks).
The last finding of the present study is that the
ldosterone-lowering actions of losartan, the prototypic
rug of the class of AT1AR antagonists (sartans) (23,24), are
ountered by adrenal arr1. Although at normal arr1 levels
control AdGFP-treated post-MI rats) it is capable of
roducing a small but significant plasma aldosterone low-
ring as expected, when adrenal arr1 is overactive
Adarr1-treated post-MI rats), losartan does not decrease
lasma aldosterone at all. This finding implies that inhibi-
ion of adrenal arr1 in vivo can facilitate the inhibitory
ffects of losartan (and possibly also of the other sartans) on
ngII-induced aldosterone production. Of note, limited
fficacy of losartan and other sartans at lowering aldosterone
evels in HF patients and in experimental animals, the
o-called “aldosterone escape,” has been reported (20,33,34).
herefore, the finding that the effects of losartan on aldoste-
one production can be antagonized by adrenal arr1-AT1R
oupling might explain (at least in part) this reported limited
fficacy of losartan and related drugs at curbing aldosterone
evels. By contrast, increased activity of the arr1 co-factor
RK2 on cardiac AT1Rs also attenuates the pro-contractile
ignaling of these receptors (26). Therefore, the development
f novel, functionally selective (or “biased”) AT1R ligands
35,36)—which would inhibit AT1R-induced GRK2/arr1
ctivation, at least as effectively as AT1R-induced G-protein
ctivation—might prove extremely beneficial in the treat-
ent of HF-related hyperaldosteronism and decreased car-
iac function.
linical implications. We have found that circulating
ldosterone levels are reciprocally regulated by adrenal arr1
ctivity in vivo, in that they are directly proportional to
arr1 activity toward AngII receptors in the adrenal glands.
herefore, inhibiting adrenal arr1 action markedly de-
reases circulating aldosterone and attenuates its detrimental
ffects on the post-MI heart—such as fibrosis, hypertrophy,
nd dilation—thereby preventing or even reversing adverse
emodeling after MI and maintaining cardiac function in
he face of post-MI-driven cardiac decline. Additionally,
osartan, a classical AngII receptor antagonist drug used in
he treatment of hypertension, seems unable to counter this
drenal arr1-promoted hyperaldosteronism after MI.
aken together, the present findings suggest adrenal arr1
s a major driving force behind post-MI aldosterone eleva-
ion, whose inhibition in vivo—either via gene therapy or
harmacologically—could potentially be of enormous ther-
peutic value in the management of post-MI HF patients.
inally, from the pharmacotherapeutic standpoint, an eval-
ation of the whole class of AT1R antagonists (sartans) in
erms of their efficacy at antagonizing arr1-driven hyper-
ldosteronism is highly warranted, because it could helpxplain some well-known existing differences in therapeutic
fficacy and also identify the most efficacious agents at
owering post-MI aldosterone, within this very important
ardiovascular drug class.
onclusions
he present study reports that adrenal arr1 promotes the
ell-documented post-MI-associated elevation of circulat-
ng aldosterone, and thus direct inhibition of its activity via
drenal-targeted gene therapy or via development of novel
T1R “biased” or “functionally selective” ligands that can
revent/reduce GRK2/arr1 activation by the AT1R might
e of therapeutic value in post-MI ensuing HF as well as in
lready established chronic HF—both of which are precip-
tated by the cardiotoxic actions of elevated aldosterone.
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